$HIMS Faces Potential Peptide Headwind as Trump’s FDA Pick Heidi Overton Is Reportedly Wary of Peptides

Trump’s pick to lead the FDA, Heidi Overton, may be “wary” of peptides, according to The Atlantic and Ars Technica.
The Atlantic previously reported that Overton was viewed by some as skeptical of the limited scientific research behind certain peptides, with one source describing her as “a skeptic of anything that is not pharma.”
The development could be relevant for $HIMS, which has exposure to the growing peptide market.